EVMN vs LLY vs KO vs ABBV vs REGN vs JPM

For growth investors, Evommune, Inc.

(EVMN) is the stronger pick with 85. 7% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 14. 8x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Evommune, Inc. (EVMN) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 14. 8x versus AbbVie Inc. at 96. 1x. On forward P/E, Regeneron Pharmaceuticals, Inc. is actually cheaper at 13. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus The Coca-Cola Company's 2. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +412.

1%, compared to +2. 0% for Evommune, Inc. (EVMN). Over 10 years, the gap is even starker: LLY returned +1485% versus EVMN's +2. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Evommune, Inc. 's 1. 63β — meaning EVMN is approximately -915% more volatile than KO relative to the S&P 500. On balance sheet safety, Evommune, Inc. (EVMN) carries a lower debt/equity ratio of 1% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Evommune, Inc.

(EVMN) is pulling ahead at 85. 7% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -529. 8% for Evommune, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -623. 6% for EVMN. At the gross margin level — before operating expenses — EVMN leads at 89. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Regeneron Pharmaceuticals, Inc. (REGN) trades at 13. 2x forward P/E versus 30. 9x for Eli Lilly and Company — 17. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EVMN: 144. 1% to $48. 40.

In this comparison, ABBV (2.

9% yield), KO (2. 5% yield), JPM (1. 9% yield), REGN (0. 6% yield), LLY (0. 5% yield) pay a dividend. EVMN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

53), 0. 5% yield, +1485% 10Y return). Evommune, Inc. (EVMN) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1485%, EVMN: +2. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EVMN (Healthcare) and LLY (Healthcare) and KO (Consumer Defensive) and ABBV (Healthcare) and REGN (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EVMN is a small-cap high-growth stock; LLY is a mega-cap high-growth stock; KO is a large-cap quality compounder stock; ABBV is a large-cap quality compounder stock; REGN is a mid-cap deep-value stock; JPM is a large-cap deep-value stock. LLY, KO, ABBV, REGN, JPM pay a dividend while EVMN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.